中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 7
Jul.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(7): 1246-1250

Clinical management of cholestatic liver disease

DOI: 10.12449/JCH250702

  • Department of Gastroenterology，The First People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine，Shanghai 200080，China

More Information
  • Corresponding author: LU Lungen， lungenlu1965@163.com （ORCID： 0000-0002-1533-4068）
  • Received Date: 2025-04-02
  • Accepted Date: 2025-05-26
  • Published Date: 2025-07-25
    Abstract
  • Cholestatic liver disease （CLD） is a group of hepatobiliary disorders caused by impaired bile production， secretion， or excretion. With the application of liquid biopsy， multi-parameter radiological examination， and genomics technology， significant progress has been made in the diagnosis and prognostic evaluation of CLD. At present， the therapeutic principles for CLD mainly focus on addressing the underlying causes and managing cholestasis， and commonly used drugs include ursodeoxycholic acid， S-adenosylmethionine， cholestyramine， fibrates， and obeticholic acid. Based on the latest clinical consensus statements and research advances in CLD， this article systematically elaborates on the clinical management strategies for CLD from the aspects of diagnosis， treatment， and prognostic evaluation.

     

    • FullText(HTML)
  • loading
    • References(38)
  • [1]
    LUO X, LU LG. Progress in the management of patients with cholestatic liver disease: Where are we and where are we going?[J]. J Clin Transl Hepatol, 2024, 12( 6): 581- 588. DOI: 10.14218/JCTH.2023.00519.
    [2]
    LU LG. Guidelines for the management of cholestatic liver diseases(2021)[J]. J Clin Transl Hepatol, 2022, 10( 4): 757- 769. DOI: 10.14218/jcth.2022.00147.
    [3]
    CHAZOUILLERES O, BEUERS U, BERGQUIST A, et al. EASL Clinical Practice Guidelines on sclerosing cholangitis[J]. J Hepatol, 2022, 77( 3): 761- 806. DOI: 10.1016/j.jhep.2022.05.011.
    [4]
    TANAKA A, MA X, TAKAHASHI A, et al. Primary biliary cholangitis[J]. Lancet, 2024, 404( 10457): 1053- 1066. DOI: 10.1016/S0140-6736(24)01303-5.
    [5]
    KARLSEN TH, FOLSERAAS T, THORBURN D, et al. Primary sclerosing cholangitis-a comprehensive review[J]. J Hepatol, 2017, 67( 6): 1298- 1323. DOI: 10.1016/j.jhep.2017.07.022.
    [6]
    BOWLUS CL, ARRIVÉ L, BERGQUIST A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma[J]. Hepatology, 2023, 77( 2): 659- 702. DOI: 10.1002/hep.32771.
    [7]
    MANNS MP, BERGQUIST A, KARLSEN TH, et al. Primary sclerosing cholangitis[J]. Nat Rev Dis Primers, 2025, 11: 17. DOI: 10.1038/s41572-025-00600-x.
    [8]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases[J]. J Hepatol, 2009, 51( 2): 237- 267. DOI: 10.1016/j.jhep.2009.04.009.
    [9]
    HARMS MH, van BUUREN HR, CORPECHOT C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2019, 71( 2): 357- 365. DOI: 10.1016/j.jhep.2019.04.001.
    [10]
    HIRSCHFIELD GM, DYSON JK, ALEXANDER GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut, 2018, 67( 9): 1568- 1594. DOI: 10.1136/gutjnl-2017-315259.
    [11]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67( 1): 145- 172. DOI: 10.1016/j.jhep.2017.03.022.
    [12]
    LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases[J]. Hepatology, 2022, 75( 4): 1012- 1013. DOI: 10.1002/hep.32117.
    [13]
    HOSONUMA K, SATO K, YAMAZAKI Y, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J]. Am J Gastroenterol, 2015, 110( 3): 423- 431. DOI: 10.1038/ajg.2015.20.
    [14]
    HONDA A, TANAKA A, KANEKO T, et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis[J]. Hepatology, 2019, 70( 6): 2035- 2046. DOI: 10.1002/hep.30552.
    [15]
    TANAKA A, HIROHARA J, NAKANO T, et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2021, 75( 3): 565- 571. DOI: 10.1016/j.jhep.2021.04.010.
    [16]
    van HOOFF MC, WERNER E, van der MEER AJ. Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid[J]. Eur J Intern Med, 2024, 124: 14- 21. DOI: 10.1016/j.ejim.2024.01.030.
    [17]
    SORET PA, LAM L, CARRAT F, et al. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis[J]. Aliment Pharmacol Ther, 2021, 53( 10): 1138- 1146. DOI: 10.1111/apt.16336.
    [18]
    ASSIS DN, BOWLUS CL. Recent advances in the management of primary sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2023, 21( 8): 2065- 2075. DOI: 10.1016/j.cgh.2023.04.004.
    [19]
    OLSSON R, BOBERG KM, de MUCKADELL OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study[J]. Gastroenterology, 2005, 129( 5): 1464- 1472. DOI: 10.1053/j.gastro.2005.08.017.
    [20]
    IMAM MH, SINAKOS E, GOSSARD AA, et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis[J]. Aliment Pharmacol Ther, 2011, 34( 10): 1185- 1192. DOI: 10.1111/j.1365-2036.2011.04863.x.
    [21]
    KOWDLEY KV, VUPPALANCHI R, LEVY C, et al. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis[J]. J Hepatol, 2020, 73( 1): 94- 101. DOI: 10.1016/j.jhep.2020.02.033.
    [22]
    TABIBIAN JH, O’HARA SP, TRUSSONI CE, et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis[J]. Hepatology, 2016, 63( 1): 185- 196. DOI: 10.1002/hep.27927.
    [23]
    DAVIES YK, COX KM, ABDULLAH BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: An immunomodulating antibiotic[J]. J Pediatr Gastroenterol Nutr, 2008, 47( 1): 61- 67. DOI: 10.1097/MPG.0b013e31816fee95.
    [24]
    DENEAU MR, MACK C, MOGUL D, et al. Oral vancomycin, ursodeoxycholic acid, or No therapy for pediatric primary sclerosing cholangitis: A matched analysis[J]. Hepatology, 2021, 73( 3): 1061- 1073. DOI: 10.1002/hep.31560.
    [25]
    LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J]. Gastroenterology, 2015, 149( 7): 1804- 1812. e 4. DOI: 10.1053/j.gastro.2015.07.061.
    [26]
    GOET JC, MURILLO PEREZ CF, HARMS MH, et al. A comparison of prognostic scores(mayo, UK-PBC, and GLOBE) in primary biliary cholangitis[J]. Am J Gastroenterol, 2021, 116( 7): 1514- 1522. DOI: 10.14309/ajg.0000000000001285.
    [27]
    CARBONE M, SHARP SJ, FLACK S, et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis[J]. Hepatology, 2016, 63( 3): 930- 950. DOI: 10.1002/hep.28017.
    [28]
    HARMS MH, de VEER RC, LAMMERS WJ, et al. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis[J]. Gut, 2020, 69( 8): 1502- 1509. DOI: 10.1136/gutjnl-2019-319057.
    [29]
    MURILLO PEREZ CF, HARMS MH, LINDOR KD, et al. Goals of treatment for improved survival in primary biliary cholangitis: Treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase[J]. Am J Gastroenterol, 2020, 115( 7): 1066- 1074. DOI: 10.14309/ajg.0000000000000557.
    [30]
    CORPECHOT C, LEMOINNE S, SORET PA, et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?[J]. Hepatology, 2024, 79( 1): 39- 48. DOI: 10.1097/HEP.0000000000000529.
    [31]
    CHEUNG AC, LAMMERS WJ, MURILLO PEREZ CF, et al. Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis[J]. Clin Gastroenterol Hepatol, 2019, 17( 10): 2076- 2084. e 2. DOI: 10.1016/j.cgh.2018.12.028.
    [32]
    CORPECHOT C, CARRAT F, GAOUAR F, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis[J]. J Hepatol, 2022, 77( 6): 1545- 1553. DOI: 10.1016/j.jhep.2022.06.017.
    [33]
    CRISTOFERI L, CALVARUSO V, OVERI D, et al. Accuracy of transient elastography in assessing fibrosis at diagnosis in Naïve patients with primary biliary cholangitis: A dual cut-off approach[J]. Hepatology, 2021, 74( 3): 1496- 1508. DOI: 10.1002/hep.31810.
    [34]
    KIM WR, THERNEAU TM, WIESNER RH, et al. A revised natural history model for primary sclerosing cholangitis[J]. Mayo Clin Proc, 2000, 75( 7): 688- 694. DOI: 10.4065/75.7.688.
    [35]
    GOODE EC, CLARK AB, MELLS GF, et al. Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system[J]. Hepatology, 2019, 69( 5): 2120- 2135. DOI: 10.1002/hep.30479.
    [36]
    de VRIES EM, WANG JF, WILLIAMSON KD, et al. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis[J]. Gut, 2018, 67( 10): 1864- 1869. DOI: 10.1136/gutjnl-2016-313681.
    [37]
    EATON JE, VESTERHUS M, MCCAULEY BM, et al. Primary sclerosing cholangitis risk estimate tool(PREsTo) predicts outcomes of the disease: A derivation and validation study using machine learning[J]. Hepatology, 2020, 71( 1): 214- 224. DOI: 10.1002/hep.30085.
    [38]
    DENEAU MR, MACK C, PERITO ER, et al. The sclerosing cholangitis outcomes in pediatrics(SCOPE) index: A prognostic tool for children[J]. Hepatology, 2021, 73( 3): 1074- 1087. DOI: 10.1002/hep.31393.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (491) PDF downloads(222) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return